samedan logo
 
 
spacer
home > pmps > summer 2021 > encompassing evolution and future perspectives
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Encompassing Evolution and Future Perspectives

The COVID-19 pandemic represented an unprecedented challenge for the pharmaceutical industry and its supply chain, with the entire sector being under continuous pressure and scrutiny from international institutions, governments, regulatory authorities, the media, and public opinion.

This was particularly relevant to the parenteral drugs market, with tensions deriving from supply continuity and the research of new treatments and vaccines to tackle and eradicate the pandemic. As mentioned, this has not only been about the pharma industry, but also its supply chain – pharma packaging included.

In the early stages of the pandemic, continuity and flexibility of supplies were the main challenges we had to overcome. The development of new vaccines against COVID-19 has led to pharma packaging producers having to provide concrete solutions for production processes in terms of the unprecedented features required, as well as the distribution of containers, and administration means.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Davide Faverzani, Head of Engineering at Bormioli Pharma, is a Mechanical Engineering graduate from the University of Parma, Italy. He has over 20 years’ experience in glass and plastic engineering. In 2004, he joined the company that later became Bormioli Pharma, holding a number of different roles with increasing responsibility over the years. Davide was also the Project Lead for the establishment of the Glass Research Center that the company opened earlier this year in collaboration with the internationally recognised Institute of Materials for Electronics and Magnetism, as part of the National Research Council.

After first working as a Project Manager, Federico Piutti now specialises as Innovation Manager. He has worked with important consultancy firms, dealing with innovation projects for national and international groups. He has managed innovation for over 10 years, developing collaborations with research centres, startups, universities, and other players in the innovation environment, both in Italy and abroad. He is in charge of Bormioli Pharma’s Open Innovation initiative, part of the Bormioli Pharma Invents corporate programme.
spacer
Davide Faverzani
spacer
spacer
spacer
Federico Piutti
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Reify Health Raises $220 Million to Eliminate Waiting in Clinical Trials

Reify Health today announced a $220 million Series C funding round led by Coatue Management, joined by ICONIQ Growth and Adams Street Partners, as well as existing investors Sierra Ventures and Battery Ventures.
More info >>

White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement